Amylin Pharmaceuticals, Inc. (AMLN) and BioCon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid Program will Focus on the Potential Treatment of Diabetes
9/11/2009 8:57:28 AM
More...
|
Mylan Inc. (MYL) Announces Strategic Collaboration with BioCon Limited to Enter the Global Generic Biologics Market
6/29/2009 7:43:38 AM
More...
|
BioCon Limited Presents Human Clinical Data on IN-105 (Oral Insulin) at the EASD Meeting in Rome
9/8/2008 8:48:09 AM
More...
|
BioCon Limited and Abraxis BioScience, Inc. Launch ABRAXANE in India for Treatment of Breast Cancer
7/18/2008 7:32:40 AM
More...
|
India's BioCon Limited to Buy U.S. Firm for $400M
4/14/2008 7:12:10 AM
More...
|
BioCon Buys 70% Stake in German Company, AxiCorp for 30M Euro
2/15/2008 7:35:03 AM
More...
|
Abraxis BioScience, Inc. and BioCon Limited Announce Approval of ABRAXANE in India for the Treatment of Breast Cancer
10/18/2007 12:44:08 PM
More...
|
Abraxis BioScience, Inc. Announces Licensing Agreement with BioCon Limited for the Commercialization of ABRAXANE in India
8/9/2007 12:52:47 PM
More...
|
Abraxis BioScience, Inc. and BioCon Limited Announce Licensing Agreement for G-CSF in North America and the European Union
7/20/2007 10:58:29 AM
More...
|
Bentley Pharmaceuticals (BNT) Signs A Licensing Agreement With Biocon Limited To Develop And Market Bentley's Intranasal Insulin Spray In 85 Countries
11/15/2005 12:58:56 PM
More...
|